A Phase I Study of Duvelisib with Either Romidepsin or Bortezomib for Recurrent or Persistent T-Cell Lymphoma


Full Title

A Phase I Trial of Duvelisib (IPI-145) in Combination with Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas


Duvelisib is a drug that works by targeting an enzyme involved in the growth of T-cell lymphoma called PI3 kinase. Studies suggest that it may work even better against this cancer when combined with romidepsin or bortezomib (drugs that are already used to treat T-cell lymphoma).

In this study, researchers are seeking the highest dose of duvelisib that can be given safely with romidepsin and with bortezomib in patients with T-cell lymphomas that have continued to grow or came back despite prior therapy. Duvelisib is taken orally (by mouth), while romidepsin is given intravenously (by vein) and bortezomib is given by injection.


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have T-cell lymphoma that has continued to grow or came back despite prior treatment.
  • Patients must recover from the serious side effects of prior therapies before entering the study.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Steven M. Horwitz at 212-639-3045.





Disease Status

Relapsed or Refractory